Jun 27, 2025, 12:04

Equity in Access Research Grants

The Equity in Access Research Program by the Leukemia & Lymphoma Society seeks to generate evidence guiding policy and practice reforms that reduce social, economic, and environmental barriers to blood cancer care. Through funding studies that implement and evaluate interventions to improve therapeutic cancer clinical trial accrual—especially among underrepresented populations—LLS aims to promote more equitable access for patients and survivors.

Eligibility Criteria

Principal investigators at academic, clinical, or non-profit institutions
Studies must focus on interventions addressing systemic, institutional, or clinician-related barriers to trial participation
Emphasis on underrepresented groups in therapeutic cancer clinical trials

Funding Details

Seed funding to support implementation and quantitative evaluation of accrual interventions
Exact budget limit not specified in LOI stage; details provided in full proposal guidelines
Projects start July 1, 2026

Deadlines & Timeline

Webinar for Applicants: June 18, 2025 (12 PM ET)
Letters of Intent Due: September 11, 2025 (3 PM ET)
Full Proposal Invitations: October 31, 2025
Full Proposals Due: January 29, 2026 (3 PM ET)
Award Notifications: April/May 2026

Where to Apply

For questions, contact [email protected]
Application guide.

blood cancer cancer clinical trials Equity in Access Research healthcare policy intervention research Letter of Intent Leukemia Lymphoma Society OncoDaily Oncology research funding RFP therapeutic trials trial accrual underrepresented populations

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips

Marty Makary: FDA Has Published More than 200 Complete Response Letters

In Memory of Zelig Eshhar: The Man Who Taught T Cells to Fight Cancer